Completed PHASE2 INTERVENTIONAL 1-arm NCT04515927

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

An Open-label, Single-arm Study Evaluated the Efficacy and Safety of JS002 in Patients With Homozygous Familial Hypercholesterolemia

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Hyperlipemia

Interventions JS002

Updated 8 times since 2020 Last updated: Jul 23, 2024 Started: Aug 17, 2020 Primary completion: May 6, 2022 Completion: Jul 29, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hyperlipemia and is currently completed. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2

Status: Unknown → Completed
Jul 2024 — Aug 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Feb 2022 — Feb 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Apr 2021 — Feb 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Junshi Bioscience Co., Ltd.

Data source: Shanghai Junshi Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China